Three-year data from a pair of European clinical trials showed that glaucoma patients implanted with a novel cilioscleral interpositioning device (CID) saw a sustained 33% reduction in intraocular pressure (IOP) compared to baseline and a 70% decrease in medication dependance, with 68% remaining medication free over the 36 months. The data was presented by French company Ciliatech at the Ophthalmology Futures European Forum.

The trials (SAFARI I and SAFARI II), which took place in Armenia, saw 41 primary open-angle glaucoma (POAG) patients implanted with Ciliatech's novel Intercil Uveal Spacer. The device is placed ab externo without ever entering the anterior chamber of the eye. There were no new safety reports since the 24-month follow up visits, and no need for additional glaucoma surgeries for any patients treated across the SAFARI studies, the company said in a press release. Ciliatech plans further global studies to advance regulatory approvals, the company said.